Dont be greedy ! Faster take your profits while it s still green ! Supermx will waterfalling this afternoon n drag all glove countets down to pre covid level !! Becareful all my friends !
Ahyuyo.... a lot of negative sentiments here... Anyway, next week... I see this will uptick. Buy now before it is too late. No need to worry... all will be good later as the company still makes tons of money.... just a hipcup. Be brave and buy/hold. No other investment is more value-added and has potential to make 20-60%. There...Some positives sentiments for you all... :)
Ya... Covid is not going to Easily go away. As sad as it is, it will be an endemic and gloves will be needed in the long run. So be safe and don't preach doom and gloom.
RHB Research showed that the single digit PE multiple for glove sector is probably the lowest compared to other sectors in Bursa. This sector is among the most profitable sectors and for this SIMPLE reason the glove sector is very undervalued. In simple terms, the current prices of glove counters especially Comfort Gloves are at a DEEP DISCOUNT from its fair value.
Its a matter of time before more market players realise that the current Comfort share price is VERY VERY CHEAP.
U.S. Infections Ease; U.K. Deaths Slow to Two: Virus Update
(Bloomberg News / May 10, 2021, 7:07 AM GMT+8)
U.S. deaths from Covid-19 have been undercounted, President Joe Biden’s top medical adviser said, with the nationwide toll approaching 582,000. New cases in the U.S. dropped over the past week to the slowest pace since the end of September. Hospitalizations dipped to a seven-month low.
With more than a third of its adult population now fully vaccinated, the U.K. reported just two virus deaths on Sunday. The European Union hasn’t renewed its order for the AstraZeneca Plc vaccine beyond June.
WHO gives emergency approval to Sinopharm, first Chinese COVID-19 vaccine
07 May 2021 11:34PM (Updated: 08 May 2021 12:11AM)
GENEVA: The World Health Organization announced on Friday (May 7) it had approved a COVID-19 vaccine from China's state-owned drugmaker Sinopharm for emergency use.
The vaccine, one of two main Chinese shots that collectively have already been given to hundreds of millions of people in China and abroad, becomes the first COVID-19 shot developed by a non-Western country to win the WHO's backing.
It is also the first time the WHO has given emergency use approval to any Chinese vaccine for any infectious disease.
A WHO emergency listing is a signal to national regulators on a product's safety and efficacy, and would allow the shot to be included in COVAX, the global programme to provide vaccines mainly for poor countries.
"This afternoon, WHO gave emergency use listing to Sinopharm Beijing's COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality," the UN health agency's director-general Tedros Adhanom Ghebreyesus told a news conference.
Tedros also said that a separate expert panel has recommended two doses of Sinopharm vaccine for those aged 18 and above.
The WHO has previously given emergency approval to COVID-19 vaccines developed by Pfizer-BioNTech, AstraZeneca, Johnson & Johnson, and, last week, Moderna.
The decision to approve Sinopharm's vaccine was taken by WHO's technical advisory group, which began meeting on Apr 26 to review the latest clinical data as well as Sinopharm's manufacturing practices.
A separate group of WHO experts, the Strategic Advisory Group of Experts (SAGE), voiced concern this week over data provided by Sinopharm on the risk of serious side-effects in some patients, but was confident in the vaccine's ability to prevent disease, according to a document reviewed by Reuters.
SAGE found an efficacy of 78.1 per cent after two doses in multi-country Phase III clinical trials, according to the document. The vaccine's developer, Beijing Biological Products Institute, a unit of Sinopharm subsidiary China National Biotec Group, had announced an efficacy of 79.34 per cent.
The WHO has said it could reach a decision on China's other main COVID-19 vaccine, made by Sinovac Biotech, as soon as next week. The technical experts reviewed it on Wednesday.
China has deployed around 65 million doses of the Sinopharm vaccine and more than 200 million doses of the Sinovac shot. Both have been exported to many countries, particularly in Latin America, Asia and Africa, many of which have had difficulty securing supplies of vaccines developed in the West.
Kyy already sold his shares in glove counters and he keeps on bashing glove counters. A sore loser? Gloves' heydays might be down from the peak but they are still making money albeit down 20 to 25% from the fantastically higher profits they are raking in. Is there a hidden agenda when Supermax emphasised on this and IBs played along
Rm 0.50 is not a dream now because Pfizer will start production in Spore soon , next time getting vaccine or oral pil is just like go to 7-11 buy gardenia ! Still dont want cut loss will suffer later !
@Reply shearer202: Consider this Analogy: Have you found that medical fees in Malaysia went down to ZERO because we have many more hospitals that can provide medical attention services?????
@WWQ188 because careplus QE come out already, hence their PE is lower that's why only natural for Careplus to perform slightly better. I think Comfort should go up also, because upcoming QR sure will post higher earnings and NP.
Lower cap gloves have higher potential to grow because they have not reach a bottleneck yet. Larger counter like top glove and supermax hard to grow already, because they expand until very hard to expand double or triple.
Comfort and Rubberex for sure can 5x their NP still
All glove counters so very cash rich, they will expand into different sources of income for sure. Each profitable glove counter is like their own investment bank, flush with cash. This is a new generation, last time is O&G. Now is glove compaines will lead the economy by leveraging on their cash.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Olive88
57 posts
Posted by Olive88 > 2021-05-07 10:31 | Report Abuse
I bought at 0.3~~•mati alr